Nothing the FDA posted today is new news. We've all known this (structure of trial, missed end points: primarily due to no clear guidance of SOC). Also, this is the same FDA that recommended and allowed Hydroxychloroquine. IMO, wait for one of the other countries to benefit from LL. Then the U.S. can pay a premium when they claim dibs.